Articles
Comparisons

Retatrutide vs Amycretin (Zenagamtide): How They Compare

Retatrutide and amycretin, now named zenagamtide, are next-generation weight-loss drugs at different stages. What each has shown, compared phase by phase.

Written By
retaweightloss.com
Updated on
07 Oct 2026
Time to read
5 min read
Category
Comparisons
Retatrutide vs amycretin (zenagamtide) comparison

Retatrutide vs Amycretin (Zenagamtide): How They Compare

Retatrutide and amycretin, now named zenagamtide, are next-generation weight-loss drugs at different stages. What each has shown, compared phase by phase.

By
RetaWeightLoss.com
Created on:
19 Jun 2026
Updated on:
07 Oct 2026
Share this post

Retatrutide vs Amycretin: The Short Answer

In their early trials, retatrutide 12 mg reduced weight by 24.2% over 48 weeks and amycretin 20 mg by 22.0% over 36 weeks, both counted as if everyone had stayed on treatment. Retatrutide is also further along: its Phase 3 trials have reported up to 28.3% weight loss over 80 weeks, while amycretin's Phase 3 obesity trials only started in 2026. Neither drug is approved.

Amycretin, which its developer now calls zenagamtide, works through GLP-1 and amylin; retatrutide works through GIP, GLP-1 and glucagon. The figures above come from separate trials of different size and length, not a head-to-head test.

Is Amycretin the Same as Zenagamtide?

Yes. Its developer, Novo Nordisk, describes zenagamtide, "also known as amycretin," as "a unimolecular peptide agonist of glucagon-like peptide-1 (GLP-1) and amylin receptors": a single molecule acting on both. Retatrutide is also a single molecule, but it acts on GIP, GLP-1 and glucagon receptors.

RetatrutideAmycretin (zenagamtide)
Developer Lilly Novo Nordisk
Receptors GIP, GLP-1 and glucagon GLP-1 and amylin
Form studied Weekly injection Weekly injection; oral form also in development
Stage in obesity Phase 3 results reported Phase 3 started in 2026
Approval status Not approved Not approved

Early-Phase Results Compared

Both drugs' first larger obesity results came from trials of under a year, reported as if everyone had stayed on treatment (the efficacy estimand).

Drug and trialParticipantsDose and lengthWeight changePlacebo
Retatrutide, Phase 2 338 12 mg, 48 weeks −24.2% −2.1%
Amycretin, phase 1b/2a 125 20 mg, 36 weeks −22.0% +2.0%


Amycretin's 22.0% came from a phase 1b/2a trial of 125 participants in which each dose was studied for a different length of time; the 20 mg dose was given for 36 weeks. Retatrutide's 24.2% came from a Phase 2 trial of 338 adults over 48 weeks. The trials differed in size, length, dose escalation and participants, so they cannot show which drug is more effective.

Type 2 Diabetes Results

At the American Diabetes Association meeting in June 2026, a 36-week Phase 2 trial of zenagamtide was presented in 262 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor. At the highest dose, 40 mg, A1C fell by 1.71 percentage points, compared with 0.14 on placebo, and weight by 14.6%, compared with 2.1%, in people who stayed on treatment without rescue medication.

Retatrutide's closest comparison is the Phase 3 TRANSCEND-T2D-1 trial (see retatrutide for type 2 diabetes), in 537 adults whose diabetes was managed with diet and exercise alone. Over 40 weeks, A1C fell by up to 2.01 points and weight by up to 16.8% if taken as intended (1.94 points and 15.3% counting everyone randomized), compared with 0.78 points and 2.5% on placebo. The trials differ in phase, length, background treatment and how results were counted.

Where Each Drug Stands

RetatrutideAmycretin (zenagamtide)
Largest obesity results TRIUMPH-1: 2,339 adults, 80 weeks, −25.0% with 12 mg counting everyone randomized Phase 1b/2a: 125 people with overweight or obesity, up to 36 weeks
Phase 3 obesity trials Reported 2025–2026 AMAZE 1 and AMAZE 2 started in 2026 (84 weeks)
Next regulatory step US submission planned for Q1 2027 Not announced


In May 2026 amycretin's developer reported that it had started AMAZE 1 and AMAZE 2, two 84-week Phase 3 trials of weekly zenagamtide injections against placebo, in people with obesity and in people with obesity and type 2 diabetes, along with further Phase 3 trials in obesity with sleep apnea, knee osteoarthritis and weight maintenance. At the EASD meeting in September 2026 it presented Phase 2b results in type 2 diabetes and named its diabetes program AMBITION; it has said that Phase 3 program is planned to start in the second half of 2026, and it is also developing an oral form of amycretin.

Retatrutide's developer has reported results from TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-1, and plans to submit retatrutide to the US Food and Drug Administration in the first quarter of 2027.

Side Effects

For both drugs, the most common side effects were gastrointestinal and mostly mild to moderate, according to the published reports. Retatrutide's trials also reported dysesthesia, an abnormal skin sensation (see retatrutide side effects). Detailed side-effect rates for amycretin from a large, long trial are not yet available, so the two safety profiles cannot be compared reliably.

What Is Still Unknown

  • How amycretin performs in Phase 3, and over 84 weeks.
  • How the two compare in the same trial; we found no head-to-head study announced by either company.
  • The long-term safety of either drug, and whether either will be approved.

Sources

  • Novo Nordisk. Company announcement on amycretin phase 1b/2a results in obesity. January 24, 2025.
  • Novo Nordisk. Q1 2026 financial report and pipeline update (AMAZE 1 and AMAZE 2). May 2026.
  • Novo Nordisk. Zenagamtide (amycretin) Phase 2 results in type 2 diabetes, presented at the American Diabetes Association Scientific Sessions. June 2026.
  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
  • Lilly Medical. TRANSCEND-T2D-1 trial summary. Reviewed May 2026.
  • Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.

Medical Disclaimer: This article compares published trial results for general information only and is not medical advice. Retatrutide and amycretin (zenagamtide) are investigational and neither is approved by the FDA for any use. Neither is available by prescription, and products sold online under their names are not sold or supplied by Lilly or Novo Nordisk. Nothing here is a recommendation to use, seek out or avoid any medication.

Frequently asked questions

Is amycretin the same as zenagamtide?

Yes. Zenagamtide is the name Novo Nordisk now uses for amycretin, a single molecule that acts on GLP-1 and amylin receptors. It is investigational and not approved, and it is being studied both as a weekly injection and as a tablet. Retatrutide is a different molecule that acts on GIP, GLP-1 and glucagon receptors.

Which works better, retatrutide or amycretin?

That cannot be said yet. They have not been compared in the same trial, and they are at different stages. In early-phase trials, retatrutide 12 mg reduced weight by 24.2% over 48 weeks and amycretin 20 mg by 22.0% over 36 weeks, both if taken as intended, but the trials differed in size, length and design.

When will amycretin's Phase 3 results be available?

No date has been announced. In 2026 Novo Nordisk started its AMAZE Phase 3 program, including two 84-week trials, AMAZE 1 and AMAZE 2, in people with obesity and in people with obesity and type 2 diabetes. Retatrutide has already reported several Phase 3 trials.

Is amycretin available as a pill?

Not yet. Amycretin is being developed both as a weekly injection and as an oral tablet, but neither form is approved. Its Phase 3 obesity trials AMAZE 1 and AMAZE 2 test the weekly injection. Retatrutide has been studied as a weekly injection.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.